A Strong Start to the New Year! “Four Key” Drug Development Drivers Propel Our Innovation Journey

Chengdu Shibeikang Biomedical Technology Co., Ltd. is kicking off the year with four major achievements in its proprietary drug development pipeline. With our differentiated metabolic innovation platform and a well-balanced portfolio of short-, medium-, and long-term projects, we’re building a sustainable ecosystem that seamlessly connects research with commercialization.

SBK007 Tablets (Chemical Class 1 New Drug): After submitting Pre-IND responses, the IND clinical application has now been officially filed.
SBK010 Oral Solution (Chemical Class 2 New Drug): Clinical acceptance number: CXHL2200851. We expect clinical approval very soon.
SBK012 Injection (Chemical Class 2 New Drug): The clinical application has been accepted (Acceptance number: CXHL2300042).
SBK002 Tablets (Chemical Class 1 New Drug): The API NDA application has been submitted, and two core departments of the evaluation center have provided written Pre-NDA responses. Once we receive the remaining feedback, we’ll submit the consolidated data for the tablet NDA.

At SBK, we are committed to our core values of “Empowering Better Health Through Inclusive Care and Support”. Driven by clinical needs, original thinking, and differentiated innovation, these “four drivers” highlight the company’s strong and sustainable innovation capabilities.